PITX1 and hepatocellular carcinoma: Sorafenib and regorafenib, both recognized as vascular endothelial growth factor receptor (VEGFR)-targeted drugs for advanced hepatocellular carcinoma (HCC) or colorectal cancer (CRC) patients, have exhibited the capacity to enhance the expression of PITX1 protein.